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There are two basic questions always
raised when biomarkers are proposed to
be used for diagnosing neurodegenerative
diseases (ND) in clinical practice (Wilner,
2010). The first question is, do biomarkers
enhance the diagnostic accuracy? Clinical-
based diagnosis accuracy of ND varies
depending on the disease, stage and the
criteria used, but in general terms it is
about 75–90% accuracy. Today, there is
consensus that several biomarkers, com-
bined with the traditional clinical process,
may allow a more accurate diagnosis in
many ND (Galluzzi et al., 2013). This fact
is particularly important in early stages,
when the diagnosis is specially challeng-
ing. For most patients with mild deficits
concerned about the development of ND,
a careful history, and a physical, neuro-
logical and neuropsychological evaluation
with a close follow-up (a “wait and see”
approach) used to be the standard prac-
tice. Today we can offer a more proactive
approach for discerning whether there is
an underlying neurodegenerative process
behind these mild deficits (Heister et al.,
2011). The National Institute on Aging-
Alzheimer’s Association criteria for AD or
MCI recommend the use of amyloid lig-
ands with caution, and only in exceptional
circumstances they should be used in clin-
ical practice (Albert et al., 2011; Sperling
et al., 2011). The use of different biomark-
ers for differential diagnosis should not
be discouraged. On the other hand, use
of biomarkers as predictive instruments
should be discouraged.
The second question is, does the addi-
tional diagnostic accuracy provided by
biomarkers really matter? In clinical prac-
tice, a test that confirmed or ruled out a
NDwould remove uncertainty. This would
also disregard or reinforce the need to
consider other diseases that may present
symptoms similar to those of ND. In some
of these diseases, prompt diagnosis can
lead to earlier effective treatment, such
as shunting for normal pressure hydro-
cephalus, supplementation with thyroid
hormones in hypothyroidism or antide-
pressive medications for depression.
The best argument for using biomark-
ers in clinical practice would be the
possibility of treating patients with a
disease-modifying therapy that prevents or
delays the progression of the disease. In
other words, putting patients on drugs
with neuroprotective effect. However, no
drug have proven prevention of any ND
yet.The current therapies only provide
symptomatic improvement at best so there
is an urgent need to discover neuroprotec-
tive treatments. But how can we conduct
clinical trials for testing such drugs when
diagnosing ND at its very early stages is so
difficult? Again, the support of biomark-
ers should be mandatory for enrolling
patients in research studies.
Then, if there is not a disease-
modifying therapy yet, what is the
importance of an early diagnosis in routine
clinical practice today? There are several
reasons to make an early diagnosis even
when we cannot modify the course of the
disease. For instance, once people become
demented, they can no longer plan for
their future or dictate their end-of-life
care. An early diagnosis of Alzheimer’s
disease gives a person the opportunity to
decide on important questions before he
or she gets demented (Martínez-Rivera
et al., 2008). It also has important conse-
quences for the patient’s family. However,
an early diagnosis of a ND may also have
negative psychological consequences in an
otherwise well-functioning person who
must now consider an inexorable decline
towards a state of illness and dependency.
Consequently, the pros and cons of early
diagnosis must be carefully weighed up
in each individual prior to perform a
confirmatory test.
And even if we have decided to use
biomarkers for supporting the diagnosis of
a ND, there are many questions to face. It
is important to emphasize that standard-
ization of these biomarkers is currently
limited, and results often vary from labo-
ratory to laboratory. Ultimately, it will be
necessary to interpret biomarker data in
the context of well-established normative
values. Moreover, procedures for acquisi-
tion and analysis of samples need to be
established to implement these biomarker
criteria on a broad scale. Although we
consider biomarkers as “negative” or “pos-
itive” for purposes of classification, it is
recognized that varying severities of an
abnormality may confer different likeli-
hoods or prognoses, which is difficult to
quantify accurately for broad application.
Currently it is difficult to understand the
relative importance of different biomark-
ers when used together, and to interpret
results when biomarker data conflict with
one another.
Equally important, there is a dearth of
truly predictive studies at the individual
subject level or in unselected populations.
The use of biomarkers in the clinical prac-
tice will require the ability to assign a
likelihood of progression in an individ-
ual person over a specific time interval
through the use of a single or multiple
biomarkers. Another major limitation is
knowledge about the timing of decline
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because the ability to detect change is
dependent on the period of observation
or prediction. A complete understanding
of the role of biomarkers in prediction of
decline will require both short and long-
term periods of observation.
Finally, little is known about out-
come when biomarkers provide conflict-
ing results. When a panel of biomarkers is
used, it is possible that for some individu-
als, one biomarker will be positive, one will
be negative, and one equivocal. The long-
term significance of such findings may also
vary with the length of follow-up.
Therefore, questions such as “what
biomarker is better for making the early
diagnosis of each ND?,” or “which one
is better for the follow up,” “which one
for making the differential diagnosis with
other disease?”, “how to interpret the
results of these tests in coordination with
clinical or genetic findings” and “how
to combine the results from different
biomarkers?” have important repercussion
on the management of patients suspected
of suffering from ND and still remain
unresponsed. The answers to these ques-
tions are not always easy and rely on
upcoming science.
We need more data and more net-
working to find appropriate conclusions.
Collaboration between basic, translational
and clinic researchers is paramount for
giving answers relevant to everyday clin-
ical practice. In this regard, the topic
research issue accompanying this edito-
rial letter gathers together a bunch of
review and original articles exploring the
use of biomarkers for ND from different
perspectives.
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